CDH1 deletions have been shown to cause cancers with immune cell infiltration, activation of targetable immune checkpoint pathways and gene expression related to T-regulatory (Treg) cell signaling, suggesting immune checkpoint potential therapeutic options [36]. This evidence concerns the gene CDH1 and cancer.